Myogen announced today that Ambrisentan®, for pulmonary arterial hypertension, met the primary efficacy endpoint and several strategic secondary endpoints in this first Phase III trial. Results are expected shortly, in 1Q06, on an additional Phase III study. To date Ambrisentan® has demonstrated: • Improvement in exercise capacity• Improvement in time to clinical worsening• An apparent [...]